HMSA Hawaii

Does HMSA Hawaii cover Zepbound?

Quick answer · Weight Loss

HMSA Hawaii covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher

Last verified June 5, 2026. Source: 14017_156760115. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What HMSA Hawaii requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, and CVD)
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Initial approval — obesity (BMI >= 30)

All of:

  • Drug used with reduced calorie diet and increased physical activity for chronic weight management in an adult
  • Patient has participated in a comprehensive weight management program (behavioral modification, reduced calorie diet, increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy
  • Baseline BMI >= 30 kg/m² (documentation required)

Initial approval — overweight with comorbidity (BMI >= 27)

All of:

  • Drug used with reduced calorie diet and increased physical activity for chronic weight management in an adult
  • Patient has participated in a comprehensive weight management program (behavioral modification, reduced calorie diet, increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy
  • Baseline BMI >= 27 kg/m² (documentation required)
  • At least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia) (documentation required)

Continuation of therapy

All of:

  • Patient has completed at least 3 months of therapy with Zepbound at a stable maintenance dose

Plus any one of:

  • Patient has lost at least 5% of baseline body weight
  • Patient has continued to maintain their initial 5% weight loss

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m² for obesity pathway, or >= 27 kg/m² for overweight pathway)
  • Documentation of qualifying weight-related comorbid condition (e.g., hypertension, T2DM, dyslipidemia) if BMI >= 27 but < 30
  • Documentation of participation in a comprehensive weight management program (behavioral modification, reduced calorie diet, increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy (initial pathway)
  • Documentation of at least 3 months of therapy at a stable maintenance dose (continuation pathway)
  • Documentation of at least 5% baseline body weight loss or maintenance of initial 5% weight loss (continuation pathway)

Quantity limits

  • 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL — 2 mL (1 package of 4 pens) / 21-day supply within 28-day fill period; 6 mL (3 packages of 4 pens each) / 63-day supply within 84-day fill period (84-day)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At continuation, patient must have lost at least 5% of baseline body weight OR continued to maintain their initial 5% weight loss. Patient must also have completed at least 3 months of therapy at a stable maintenance dose. The 6-month lifestyle program requirement is NOT re-checked at continuation, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Coadministration with other tirzepatide-containing products is not recommended
  • Coadministration with any GLP-1 receptor agonist is not recommended
  • Coadministration with other weight management products (prescription, OTC, or herbal) has not been established
  • Not studied in patients with history of pancreatitis

Policy note: Policy number 6192-C, updated UDR 11-2023. Two distinct pathways exist: (1) new start requiring prior 6-month lifestyle program plus BMI criteria, and (2) continuation requiring 3 months at stable dose plus 5% weight loss or maintenance. The quantity limit note specifies 21-day and 63-day supply durations to allow time for refill processing within 28-day and 84-day fill windows respectively. No OSA-specific indication criteria are documented in this policy despite OSA being listed as an FDA-approved comorbidity for the overweight (BMI >= 27) threshold.

verified June 5, 2026 · source: 14017_156760115

Why Zepbound requests get denied by HMSA Hawaii

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does HMSA Hawaii cover Zepbound?
HMSA Hawaii covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance.
What BMI do you need for Zepbound under HMSA Hawaii?
For weight loss on Employer / Commercial Insurance plans, HMSA Hawaii requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Zepbound approval last with HMSA Hawaii?
Initial approvals last 8 months, and renewals are granted in 12-month periods.
What does HMSA Hawaii require to renew Zepbound?
At least 5% weight loss from the starting weight, At continuation, patient must have lost at least 5% of baseline body weight OR continued to maintain their initial 5% weight loss. Patient must also have completed at least 3 months of therapy at a stable maintenance dose. The 6-month lifestyle program requirement is NOT re-checked at continuation, and at least 12 weeks on therapy before the first renewal.
How current is this information?
This page reflects HMSA Hawaii's written policy as of its current version, last verified against the source document on June 5, 2026.

Other medications under HMSA Hawaii

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes HMSA Hawaii's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.